Publications by authors named "Manuel Ruiz Borrego"

Claim this Profile
C
Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].
Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Manuel Ruız-Borrego

Breast· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
Manuel Ruiz Borrego, David Páez López-Bravo, Mireia Margelí Vila, José Manuel Pérez-García, María Fernández

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
Miguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, Manuel Ruiz-Borrego, Noelia Martinez Jañez

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Thorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, Manuel Ruiz-Borrego, María Valero

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Rupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, María Gion, Manuel Ruiz-Borrego

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.
Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Manuel Ruız-Borrego

Breast· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, Christos Vaklavas, Irene Moreno

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.
Federico Rojo, Clive R Taylor, Carlos Barrios, Laura Torrecillas, Manuel Ruiz-Borrego

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, Eva Carrasco, Gonzalo Spera, Manuel Ruiz-Borrego

Oncologist· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.
José A García-Saenz, Gonzalo Spera, Marina Pollán, Begoña Bermejo, Manuel Ruiz-Borrego

Int J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, María Gion, Richard Greil, Manuel Ruiz-Borrego

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé, Manuel Ruiz-Borrego

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Manuel Ruiz-Borrego

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.
José Manuel Pérez-García, María Gion, Manuel Ruiz-Borrego, Isabel Blancas, Elena López-Miranda

EClinicalMedicine· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.
Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruiz-Borrego

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.
Antonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, Audrey Hennequin, Adela Fernández-Ortega, Manuel Ruiz-Borrego

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Manuel Ruiz-Borrego

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.
Maximilian Marhold, Marta Vaz Batista, Isabel Blancas, Cristina Morales, Cristina Saura-Manich, Manuel Ruíz-Borrego

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.
Sara Lopez-Tarruella, Marina Pollán, Eva Carrasco, Raquel Andrés, Miguel Martín, Manuel Ruiz-Borrego

Oncologist· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Manuel Ruíz Borrego

N Engl J Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.
Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós, José Ángel García-Sáenz, Patricia Cortez, Manuel Ruiz-Borrego

Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego

Lancet Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Isabel Miras, Ana Gil, Marta Benavent, María Ángeles Castilla, Begoña Vieites, Manuel Ruiz-Borrego

Ther Adv Med Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.
Manuel Ruiz Borrego, Yen-Shen Lu, Felipe Reyes-Cosmelli, Yeon Hee Park, Toshinari Yamashita

Breast Cancer Res Treat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.
David M Hyams, Avital Bareket-Samish, Juan Enrique Bargallo Rocha, Sebastian Diaz-Botero, Sandra Franco, Manuel Ruiz Borrego

J Surg Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis